Sepsis, a life-threatening condition triggered by the body’s overwhelming response to infection, leaves a significant number of survivors grappling with debilitating long-term effects – and a newly published study reveals a key mechanism driving one of the most persistent: muscle weakness. This isn’t simply a matter of deconditioning during illness; research indicates that damage to … Read more
Postpartum Complications: The Emerging Era of Extended Maternal Monitoring Nearly 50% of severe maternal morbidity cases occur after hospital discharge, extending up to six weeks postpartum – a startling revelation that challenges conventional healthcare timelines. This isn’t simply a matter of refining existing protocols; it signals a fundamental need to redefine the postpartum period and … Read more
Sepsis, a life-threatening condition arising from the body’s overwhelming response to infection, remains a stubbornly difficult clinical challenge. Despite decades of research focused on suppressing the initial inflammatory surge, treatment strategies consistently fail in late-stage trials. New research published in Burns & Trauma reveals a critical piece of this puzzle: a previously unappreciated mechanism by … Read more
Early Tuberculosis Treatment: A Paradigm Shift in Combating Sepsis and HIV Co-infection Nearly 11 million people fell ill with tuberculosis in 2023, and sepsis claims the lives of over 11 million people annually – a number projected to rise dramatically with increasing antimicrobial resistance. But a groundbreaking study from UVA Health is revealing a critical … Read more
The boundaries of respiratory care have been dramatically redefined. A recent case study, published in Med, details the successful use of a novel total artificial lung (TAL) system to keep a patient alive after a complete bilateral pneumonectomy – the removal of both lungs – paving the way for a life-saving transplant. This isn’t simply … Read more
A potential turning point in the fight against sepsis has emerged from a Phase 2 clinical trial in China, offering hope for a condition that claims millions of lives annually. Researchers at Griffith University are poised to advance a novel drug candidate, STC3141, into Phase 3 trials, fueled by promising results indicating a significant reduction … Read more